FectoVIR®-AAV transfection reagent is a novel chemical-based and animal-free transfection reagent that has been engineered to address the current limits in rAAV viral vector yields and industrial scalability. FectoVIR®-AAV transfection reagent is the outcome of an extensive development process in which candidates from our proprietary internal chemical library were tested in comparison to the gold standard for virus production, our PEIpro® transfection reagent. In comparison to PEIpro® and other competitors, FectoVIR®-AAV stands out with its unmatched performance for the production of rAAV viral vectors in suspension cell culture systems:
- Designed for Gene Therapy: RUO and cGMP grade for process development to commercialization
- Superior Performance: highest AAV titers to increase dose number per batch
- Scalable: robust and flexible for small to large scale production
- Cost-effective: reduce cost per dose for therapy affordability
- Accelerate time to market: combine performance and scalability for speedy process development
- Trustworthy: access to our Gene therapy scientific, regulatory and supply chain support